Capricor Therapeutics, Inc. (FRA:4LN2)
Germany flag Germany · Delayed Price · Currency is EUR
18.50
+0.56 (3.12%)
Last updated: Jan 30, 2026, 3:25 PM CET

Capricor Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
11.1322.2725.182.550.240.31
Revenue Growth (YoY)
-52.08%-11.55%886.81%941.85%-21.06%-69.13%
Cost of Revenue
75.8849.9736.4521.8213.578.46
Gross Profit
-64.75-27.7-11.27-19.27-13.33-8.15
Selling, General & Admin
21.9414.8712.8110.437.615.54
Operating Expenses
21.9414.8712.8110.437.615.54
Operating Income
-86.68-42.56-24.08-29.7-20.94-13.69
Interest & Investment Income
4.922.21.730.520.060.03
Other Non Operating Income (Expenses)
0.040.010.07---
EBT Excluding Unusual Items
-81.72-40.35-22.28-29.18-20.88-13.66
Gain (Loss) on Sale of Assets
-0.27-0.11-0.01-0.03-0.01-
Other Unusual Items
---0.190.87-
Pretax Income
-81.99-40.47-22.29-29.02-20.02-13.66
Net Income
-81.99-40.47-22.29-29.02-20.02-13.66
Net Income to Common
-81.99-40.47-22.29-29.02-20.02-13.66
Shares Outstanding (Basic)
453527252316
Shares Outstanding (Diluted)
453527252316
Shares Change (YoY)
43.02%31.52%9.06%6.34%48.28%319.55%
EPS (Basic)
-1.81-1.15-0.83-1.18-0.87-0.88
EPS (Diluted)
-1.81-1.15-0.83-1.18-0.87-0.88
Free Cash Flow
-68.38-41.53-27.641.56-18.01-10.6
Free Cash Flow Per Share
-1.51-1.18-1.030.06-0.78-0.68
Gross Margin
--124.37%-44.76%---
Operating Margin
-778.80%-191.13%-95.63%-1163.93%-8549.86%-4412.56%
Profit Margin
-736.62%-181.71%-88.52%-1137.37%-8175.86%-4401.94%
Free Cash Flow Margin
-614.30%-186.50%-109.79%61.02%-7352.29%-3417.38%
EBITDA
-84.92-41.14-23.01-29.16-20.69-13.55
EBITDA Margin
--184.73%-91.39%---
D&A For EBITDA
1.761.431.070.530.250.14
EBIT
-86.68-42.56-24.08-29.7-20.94-13.69
EBIT Margin
--191.13%-95.63%---
Revenue as Reported
11.1322.2725.182.550.240.31
Source: S&P Global Market Intelligence. Standard template. Financial Sources.